Department of Obstetrics and Gynecology, The Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi 533000, P.R. China.
Department of Obstetrics and Gynecology, The Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R.China.
Asian Pac J Cancer Prev. 2023 Jun 1;24(6):2003-2010. doi: 10.31557/APJCP.2023.24.6.2003.
The aim of this study is to evaluate the expression of syntaxin 6 (STX6) in epithelial ovarian cancer (EOC) and assess the effects of STX6 on the prognosis of patient.
Using information from the Kaplan-Meier Plotter database, the effects of STX6 expression on overall survival (OS) and progression-free survival (PFS) in ovarian cancer patients were examined. The clinical information of 147 patients with epithelial ovarian cancer was evaluated, and immunohistochemical staining was used to identify STX6 expression in postoperative tumor specimens, and the affection of STX6 expression on patient prognosis was assessed. In addition, the expression of STX6 in tumor tissue, peritoneal metastases (PM) derived from 13 patients with epithelial ovarian cancer and 6 normal ovarian specimens was detected by PCR and Western blot. In order to investigate how STX6 affects the proliferation of tumor cells, STX6 was also over expressed and knock down in ovarian cancer cell lines. Then colony formation assay was used to explore the effect of STX6 regulating on cell proliferation.
Kaplan-Meier Plotter enrollment data analysis revealed that patients with overexpressed STX6 had substantially worse OS and PFS than individuals with low STX6 expression. Retrospective study revealed a significant (P<0.05) correlation between the STX6 expression and tumor classifications, tumor stage, peritoneal carcinomatosis index (PCI), and PFS survival of patients. Western blot and PCR findings for fresh samples showed that STX6 was overexpressed in both primary lesions and PM nodules of OC. SKOV3 cell proliferation was shown to be dramatically reduced by STX6 knockdown and promoted by STX6 overexpression, according to the in vitro experiments.
STX6 may increase the progression of epithelial OC by encouraging the proliferation of cancer cells, indicating that STX6 was a viable therapeutic target of epithelial OC.
本研究旨在评估突触结合蛋白 6(STX6)在卵巢上皮癌(EOC)中的表达,并评估 STX6 对患者预后的影响。
利用 Kaplan-Meier Plotter 数据库中的信息,研究 STX6 表达对卵巢癌患者总生存期(OS)和无进展生存期(PFS)的影响。评估了 147 例上皮性卵巢癌患者的临床资料,采用免疫组织化学染色方法检测术后肿瘤标本中 STX6 的表达,并评估 STX6 表达对患者预后的影响。此外,通过 PCR 和 Western blot 检测了 13 例上皮性卵巢癌患者和 6 例正常卵巢标本的肿瘤组织和腹膜转移(PM)中 STX6 的表达。为了研究 STX6 如何影响肿瘤细胞的增殖,还在卵巢癌细胞系中过表达和敲低了 STX6。然后,通过集落形成实验来探索 STX6 调节细胞增殖的作用。
Kaplan-Meier Plotter 登记数据分析显示,STX6 过表达的患者 OS 和 PFS 明显低于 STX6 低表达的患者。回顾性研究显示,STX6 表达与肿瘤分类、肿瘤分期、腹膜癌指数(PCI)和患者 PFS 生存之间存在显著(P<0.05)相关性。对新鲜样本的 Western blot 和 PCR 结果显示,OC 的原发灶和 PM 结节中均过表达 STX6。体外实验表明,STX6 敲低可显著抑制 SKOV3 细胞增殖,而过表达 STX6 则促进其增殖。
STX6 可能通过促进癌细胞增殖而加速上皮性 OC 的进展,表明 STX6 是上皮性 OC 一个可行的治疗靶点。